Century Therapeutics, Inc. Common Stock

IPSCNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
1.33 USD
↗ 0.01 (0.76%)🟢PRE MARKET (AS OF 04:04 AM EDT)
🟢Market: OPEN

IPSC is currently priced at $1.33. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Oct 6, 2026.

Open?$1.33
High?$1.33
Low?$1.33
Prev. Close?$1.32
Volume?30
Avg. Volume?582.5K
VWAP?$1.33
Rel. Volume?0.00x
Bid / Ask
Bid?$1.09 × 100
Ask?$1.54 × 100
Spread?$0.45
Midpoint?$1.32
Valuation & Ratios
Market Cap?239.0M
Shares Out?181.1M
Float?124.7M
Float %?69.1%
P/E Ratio?N/A
P/B Ratio?1.03
EPS?-$0.61
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Themes
Biotech - Drug Development›Immunology & AutoimmuneHealthcare - Oncology›Cell & Gene Therapy for Cancer
Employees
78
Market Cap
239.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.centurytx.com
Listed
2021-06-18
Address
25 N 38TH STREET, 12TH FLOOR
PHILADELPHIA, PA
Phone: 215-981-4000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
39
Piotroski F-Score?0/9Weak
Altman Z-Score?-2.40Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?23.55%Squeeze Risk
Short Interest?29.4M
Days to Cover?78.6
Free Float124.7M
Avg Daily Volume373.3K
Settlement Date2026-09-15
Financial Health
Current Ratio?8.28Strong
Quick Ratio?8.28Strong
Cash Ratio?3.29Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
1.03CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.2CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-47.3%WEAK▾
ROA?
S&P
3
-38.3%WEAK▾
Cash Flow & Enterprise
FCF?$-88091000
Enterprise Value?$189.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist